By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we fund research that can change how neuroendocrine cancers
Neuroendocrine neoplasms (NENs) can be difficult to detect, and many patients face long delays before receiving an accurate diagnosis. In many cases, NENs are not
By Carrie Camino, Member, NETRF Board of Directors Last month I had the extraordinary opportunity to attend the American Association of Cancer Research (AACR) as
By Anna C. Greene, PhD, NETRF Chief Scientific Officer The American Association for Cancer Research Annual Meeting, known as AACR, is one of the largest
Research-informed answers to your most important questions about neuroendocrine cancer. By Anna C. Greene, PhD, Chief Scientific Officer, Neuroendocrine Tumor Research Foundation (NETRF) You asked.
Leo Giancola lost his mom Ivette Giancola to neuroendocrine cancer when he was still in kindergarten. While his memories of her at that age are
When we launched Breakthroughs Today, Cures Tomorrow, we made a promise: to accelerate the science that leads to better treatments and, ultimately, cures for neuroendocrine
More than 1,100 patients and caregivers from across the United States and internationally participated in NETRF’s 2026 Annual Patient and Caregiver Survey, sharing their experiences,
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Two recent NETRF-funded studies are offering new insight into how neuroendocrine tumors grow, spread, and respond
At the Neuroendocrine Tumor Research Foundation (NETRF), we support research that can move the field forward, not only by advancing new treatments, but also by